Introduction. Epilepsy is one of the most common neurological disorders. Epileptic patients taking antiepileptic pharmaceuticals often suffer from hypertrophic changes in gums. It is well established that dental hypertrophies within the alveolar tissue appear more often in children and young people being treated for epilepsy than adults. Aim. The aim of the study was to determine the influence of antiepileptic drug therapy on the oral cavity of both children and young people suffering from epilepsy. Material and methods. The investigation consisted of a clinical examination and a questionnaire looking at 107 individuals of both sexes, all aged between 6 and 18. They were all residents of the Lublin region. The study looked at the individuals residing in the Social Care Center in Lublin and patients treated at the Children’s Clinical Hospital in Lublin. The oral analysis included an examination of hard tissues, the state of oral hygiene according to Green and Vermillion (OHI-S), periodontal treatment needs (CPITN), status of gums and mucosal membrane pathological assessment of the oral cavity and determination of developmental disturbances of teeth (intensity of tooth decay expressed as DMFt). Results. The patients who took antiepileptic drugs had greater treatment needs in tissues of periodontium - determined by the value of CPITN index - (1.68±0.60), unlike those subjects who had not taken any medicine (0.96±0.29), (p=0.0001; Z=-3.20). It was stated that the value of the DMFt index had been significantly higher in those subjects who had been taking antiepileptic medicines (6.80±5.16), unlike the subjects not taking medicine (4.65±3.72), (p=0.02; Z=2.40). In subjects taking antiepileptic drugs, the OHI-S index was significantly higher (2.50) unlike those subjects who had not taken any medicine (1.53), (p=0.0001; Z=4.92). Conclusions. The findings demonstrate that the hard dental tissues in children taking antiepileptic drugs require much more care. They have a higher simplified index of oral hygiene and higher index for periodontal treatment needs. Disturbances related to oral mucosal cavity and dental abnormalities occurred more frequently in children ingesting antiepileptic agents
Familial incidence of dentinogenesis imperfectaa case studyDentinogenesis imperfecta (incomplete development of dentine, Capdepont's illness, opalising dentine), is a genetic disorder inherited in autosomal, dominant way, from one patient to another. There occur asymptomatic carriers of the gene (2, 3). This is the illness developing with the excess of abnormality of mesoderm tissue and is concerned with dentine. It occurs rarelyone case in seven in 10,000 individuals (according to Magnusson) (3). It could be an independently existing illness type II and III (according to Shield) or it could occur as one of the symptoms of osteogenesis imperfecta (type I according to Shield) (1,3,4,8). It is concerned with milk and permanent teeth. Clinically the teeth are discoloured into amber-like colour, grayish-yellow-brown and possess characteristic opalisation. The crowns take bell-like or bulging shape, the roots are shortened and disfigured. There occurs partial or total obliteration of tooth cavities, short and narrow canals. The teeth, shortly after coming out, undergo pathological abrasion (3-5). Histological structure in dentinogenesis imperfecta is improper. The enamel layer is thin, but composed properly. The dentine in the external part shows proper structure and in the para-ventricular part is improper with the canals of a disturbed shape and course; it has got irregular inter-spherical spaces. One may notice the remaining of the pulp tissues. In the pulp, there occur thick collagen fibres, but odontoblasts are regular. The reason for teeth abrasion is the improper structure of dentine and enamel-dentine junction (1,3,(6)(7)(8).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.